Published on Fri Mar 26 2021

Pathologic upgrading in favorable intermediate risk active surveillance patients: Clinical heterogeneity and implications for active surveillance decision.

Rashid K Sayyid, William C Reed, John Z Benton, Atul Lodh, Phillip Woodruff, Joshua H Lambert, Martha K Terris, Christopher J D Wallis, Zachary Klaassen

Current guidelines support active surveillance (AS) for select patients with favorable intermediate risk (FIR) prostate cancer (CaP) A significant proportion of FIR CaP patients undergoing surgical treatment are found to have evidence of adverse pathology.

1
1
5
Abstract

Current guidelines support active surveillance (AS) for select patients with favorable intermediate risk (FIR) prostate cancer (CaP). A significant proportion of FIR CaP patients undergoing surgical treatment are found to have evidence of adverse pathology. Our objective was to determine the incidence and predictors of pathologic upgrading in FIR AS patients undergoing radical prostatectomy.